Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia

Neurourology and Urodynamics

Volumn 25, Issue 7, 2006, Pages 792-799

  Tatemichi, Satoshi ^a   Tomiyama, Yoshitaka ^a   Maruyama, Itaru ^a   Kobayashi, Shinya ^a   Kobayashi, Kumi ^a   Maezawa, Ayaka ^a   Kobayashi, Mamoru ^a   Yamazaki, Yoshinobu ^a   Shibata, Nobuo ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

1A adrenoceptor subtype; Dog; Silodosin (KMD 3213); Uroselectivity

Indexed keywords

8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; PRAZOSIN; SILODOSIN; TAMSULOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; HYPOGASTRIC NERVE; IN VITRO STUDY; IN VIVO STUDY; MALE; NERVE STIMULATION; NONHUMAN; PROSTATE; PROSTATE HYPERTROPHY; URETHRA PRESSURE; URINARY TRACT OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CAROTID ARTERY, COMMON; DATA INTERPRETATION, STATISTICAL; DOGS; ELECTRIC STIMULATION; HEART RATE; HYPOGASTRIC PLEXUS; INDOLES; MALE; NAPHTHALENES; NOREPINEPHRINE; ORGAN SPECIFICITY; PIPERAZINES; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; URETHRA; URETHRAL OBSTRUCTION; URINARY TRACT;

EID: 33750623277     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20312     Document Type: Article

References (36)

1. AUA Practice Guidelines Committee. 2003. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170:530-47.
2. Brendler CB, Berry SJ, Ewing LL, et al. 1983. Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. J Clin Invest 71:1114-23.
3. Brune ME, Katwala SP, Milicic I, et al. 2002. Effect of fiduxosin, an antagonist selective for alpha 1A- and alpha 1D-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J Pharmacol Exp Ther 300:487-94.
4. Cavalli A, Lattion AL, Hummler E, et al. 1997. Decreased blood pressure response in mice deficient of the alpha 1b-adrenergic receptor. Proc Natl Acad Sci USA 94:11589-94,
5. Faure C, Gouhier C, Langer SZ, et al. 1995. Quantification of alpha 1-adrenoceptor subtypes in human tissues by competitive RT-PCR analysis. Biochem Biophys Res Commun 213:935-43.
6. Goetz AS, Lutz MW, Rimele TJ, et al. 1994. Characterization of alpha 1-adrenoceptor subtypes in human and canine prostate membranes. J Pharmacol Exp Ther 271:1228-33.
7. Hampel C, Dolber PC, Smith MP, et al. 2002. Modulation of bladder alpha 1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167:1513-21.
8. Hancock AA, Buckner SA, Brune ME, et al. 2002. Preclinical pharmacology of fiduxosin, a novel alpha 1-adrenoceptor antagonist with uroselective properties. J Pharmacol Exp Ther 300:478-86.
9. Hatano A, Takahashi H, Tamaki M, et al. 1994. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723-8.
10. Hieble JP, Bylund DB, Clarke DE, et al. 1995. International Union of Pharmacology X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update. Pharmacol Rev 47:267-70.
11. Hoo KH, Kwan CY, Daniel EE. 1994. Investigation of alpha 1-adrenoceptor subtypes in canine aorta, using alkylating agents. Can J Physiol Pharmacol 72:97-103.
12. Hosoda C, Tanoue A, Shibano M, et al. 2005. Correlation between vasoconstrictor roles and mRNA expression of alpha 1-adrenoceptor subtypes in blood vessels of genetically engineered mice. Br J Pharmacol 146:456-66.
13. Imagawa J, Akima M, Sakai K. 1989. Functional evaluation of sympathetically mediated responses in in vivo lower urinary tract of dogs. J Pharmacol Methods 22:103-11.
14. Johnston SD, Kamolpatana K, Root-Kustritz MV, et al. 2000. Prostatic disorders in the dog. Anim Reprod Sci 60-61:405-15.
15. Kawabe K. 2006. Latest frontiers in pharmacotherapy for benign prostatic hyperplasia. Yakugaku Zasshi 126:199-206.
16. Lepor H, Shapiro E. 1984. Characterization of alpha 1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 132:1226-9.
17. Lepor H. 1993. Medical therapy for benign prostatic hyperplasia. Urology 42:483-501.
18. Lepor H, Zhang W, Kobayashi S, et al. 1994. A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Ther 270:722-7.
19. Low AM, Lu-Chao H, Wang YF, et al. 1998. Pharmacological and immunocytochemical characterization of subtypes of alpha-1 adrenoceptors in dog aorta. J Pharmacol ExpTher 285:894-901.
20. Malloy BJ, Price DT, Price RR, et al. 1998. Alpha 1-adrenergic receptor subtypes in human detrusor. J Urol 160:937-43.
21. Marshall I, Burt RP, Chapple CR. 1995. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Br J Pharmacol 115:781-6.
22. Monda JM, Oesterling JE. 1993. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin Proc 68:670-9.
23. Muramatsu I, Kigoshi S, Ohmura T. 1991. Subtypes of alpha 1-adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. Jpn J Pharmacol 57:535-44.
24. Murata S, Taniguchi T, Takahashi M, et al. 2000. Tissue selectivity of KMD-3213, an alpha 1-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 164:578-83.
25. Nasu K, Moriyama N, Fukasawa R, et al. 1998. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123:1289-93.
26. Nasu K, Moriyama N, Kawabe K, et al. 1996. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119:797-803.
27. Poirier M, Riffaud JP, Lacolle JY, et al. 1988. Effects of five alpha-blockers on the hypogastric nerve stimulation of the canine lower urinary tract. J Urol 140:165-7.
28. Price DT, Schwinn DA, Lomasney JW, et al. 1993. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 150:546-51.
29. Shibata K, Foglar R, Horie K, et al. 1995. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48; 250-8.
30. Takei R, Ikegaki I, Shibata K, et al. 1999. Naftopidil, a novel alpha 1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol 79:447-54.
31. Tanoue A, Nasa Y, Koshimizu T, et al. 2002. The alpha 1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 109:765-75.
32. Tatemichi S, Kobayashi K, Maezawa A, et al. 2006. Alpha 1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126:209-16.
33. Villalobos-Molina R, Lopez-Guerrero JJ, Ibarra M. 1999. Functional evidence of alpha 1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. Br J Pharmacol 126:1534-6.
34. Walden PD, Durkin MM, Lepor H, et al. 1997. Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 157:1032-8.
35. Yamada S, Suzuki M, Kato Y, et al. 1992. Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy. Life Sci 50:127-35.
36. Yoshida M, Kawabe K, Homma Y. 2005. Silodosin, Abstracts of papers, the 100th Annual Meeting of the American Urological Association, San Antonio, May 2005, J Urol 173:p445a.